Vitrolife AB (publ) (VITR) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to the Vitralife Group Q4 report. I'll now move you to the first slide of the presentation. Let me start with the highlights. We delivered 6% organic growth in local currencies, excluding discontinued business, beating our own internal forecast for the quarter in relation to the top line. Strong growth in Americas, again driven by North America. I should also call out that APAC also performed very well in the quarter with 10% organic growth in local currencies. And the third point that I would like to highlight is that following a strategic review of our genetic services business, we announced a restructuring program in December. This will allow us to focus on the key tests and markets with stronger prospects for profitable growth. I'll now move you on to the next slide, please, and take you through the key highlights. So sales in the fourth quarter were 891 million SEIC, an organic growth in local currencies of 6%, as I mentioned, but significantly impacted by minus 10% from currency effects. Gross margin was 58.6 when adjusted for the restructuring. This was a decrease versus Q4 2024, which was exceptionally strong. Additional factors impacting the gross margin are a currency impact, which is the majority, in fact, the regional mix. So you will see in the coming slides, we are increasingly having a greater percentage of our revenue coming from Americas, And then we also have a mix effect within consumables in APAC, where we had a targeted campaign in disposable devices. Moving down then to EBITDA, we had EBITDA of 251 million SEC in the quarter, equating to an EBITDA margin of 28.2%. We also have a significant negative currency impact here, just under 3%. um regional mix and product mix as i mentioned also in relation to margin i...